| INTRODUCTION
Human herpesvirus 6 (HHV-6) is a lymphotropic virus first isolated from peripheral blood lymphocytes of patients suffering from lymphoproliferative disorders. 1 Whilst initially referred to as "strain variants," HHV-6A and HHV-6B are now recognized by the International Committee for the Taxonomy of Viruses (ICTV) as distinct virus species based on genotypic and phenotypic differences (differential tropism in cell culture) and clinical distinctions.
rash that often follows primary infection which is almost ubiquitous in early childhood 4, 5 and HHV-6B is also associated with febrile illness in young children. 6, 7 Whilst older studies do not include genotype analysis, it is known from more recent studies that 99 to 100% of primary infections in America, Europe, and Japan are with HHV-6B. 2, 8 In addition to Roseola infantum, which is often mild and self-resolving, in a subset of cases there is evidence of neurological involvement, sometimes manifesting as seizures or convulsions 6, 9 and also more severe encephalitis due mostly to reactivated infections in immunocompromised adults. [10] [11] [12] [13] [14] HHV-6B has also been linked with mesial temporal lobe epilepsy (MTLE). [15] [16] [17] HHV-6A is rarely detected in children in Western countries, but two Zambian studies have detected HHV-6A readily in blood or sera specimens from children. 18, 19 An in vitro study has also shown that both HHV-6A and HHV-6B can productively infect human fetal astrocytes, causing multinucleated syncytia, with progeny virions maintaining T-cell tropism, 20 evidence that HHV-6 is able to directly infect and cause pathology in central nervous system (CNS) tissue.
The most common seizures suffered by children in early childhood are clinically defined as "simple febrile seizure (FS)," lasting less 22 There are 13 studies which have screened for HHV-6 infection in children with febrile illness or FS, comprising five casecontrol and eight cross-sectional studies. The most prominent of these is a large prospective study from the US where 9.7% (160/ 1653) of febrile children had primary HHV-6 infection (defined by seroconversion and PCR detection of HHV-6 virus). 6 Among the 160 cases of primary HHV-6 infection, 21 (13.1%) were admitted to hospital with FS, with primary HHV-6 infection being detected in one-third of all FS cases. 6 Comparing febrile children with and without seizures, the rates of HHV-6 infection were over threefold higher in those with FS. 6 However, results from four subsequent case-control studies did not find any difference in HHV-6B prevalence between children with and without seizures. [23] [24] [25] [26] With respect to children with complex seizures and status epilepticus a link with HHV-6 has been suggested in three studies. 9, 27, 28 In the most recent study (consequences of prolonged seizures in childhood
[FEBSTAT]) the prevalence of HHV-6 infection at baseline was 32%
(54/169) in children with FSE, but no clinical distinctions could be made between patients with and without HHV-6B infection. 27 The available data points towards a possible association between HHV-6B and both FS and/or FSE, but no studies have demonstrated a causal relationship. 29 The prevalence of epilepsy in sub-Saharan Africa is double that in developed countries 30 and as CNS infections are a major risk factor for FSE and epilepsy 30, 31 there is a need for studies to evaluate cases were coinfected with HHV-6B. 34 PCR studies in Zambia on sera from healthy children also identified highly prevalent HHV-6A
infections. 18 Another study also from Zambia screened for HHV-6 in lung tissue (taken at autopsy) 18 and sera specimens from children admitted with respiratory disorders, where HHV-6B was more prevalent. 35 We present here the first case-control study from the Africa region comparing HHV-6 infection rates in admitted febrile children with and without seizures, and also comparing those with and without FSE, the largest study of its kind to be undertaken since the Hall study of 1994.
2 | METHODS
| Study objectives
To determine whether there is an association between HHV-6A
and/or HHV-6B infection and FS in children admitted with febrile illness to the University Teaching Hospital (UTH), Lusaka, Zambia.
and/or HHV-6B infection and FSE, in children admitted to the UTH with febrile illness.
| Ethical considerations
Ethical approval was sought from the Research Ethics Committee.
Permission was obtained from the University Teaching Hospital
Department of Pediatrics to conduct the study. Written consent was obtained from the parents/guardians of the participants as they were aged between 6 and 60 months of age.
| Study definitions
For the purpose of the study, fever was defined as an axillary temperature of 37.5°C and above. 
| Recruitment
The study enrolled children between the ages of 6 months to 60 months from January 2015 to May 2016. The study recruited patients from the pediatric emergency department and the admissions ward the University Teaching Hospital in Lusaka, Zambia. The facility is a tertiary referral center receiving cases from various parts of Lusaka as well as referral cases from all over the country.
| Inclusion and exclusion criteria
Inclusion criteria included:
1. Any child aged 6 to 60 months with first episode of FS and FSE presenting within 48 hours of a FS. These were our cases.
2. Any child aged 6 to 60 months with a febrile illness without seizures presenting within 48 hours of a febrile illness. These were our controls.
Exclusion criteria included:
1. Children with signs and symptoms of CNS infection (eg, neck stiffness, positive Brudzinski sign, positive Kernig sign and persistent altered level of consciousness) were excluded.
Children with clinical evidence of CNS anomalies such as
hydrocephalus, cerebral palsy and microcephaly were excluded.
3. Children younger than 6 months or older than 60 months were excluded.
4.
Children with known seizure disorders were excluded.
5.
Children already enrolled in other studies were excluded.
| Plasma collection and DNA extraction
Three milliliters of blood was collected from a peripheral vein and placed in labeled ethelenediamine tetra-acetic acid (EDTA) tubes and spun. The plasma was drawn from the tubes and stored at −81°C for later testing.
Plasma samples had DNA-extracted using the QIAGEN QIAamp ® DNA Mini Kit according to the manufacturerʼs specifications.
| HHV-6 PCR assay
Real-time Taqman PCR was undertaken using consensus primers detecting both HHV-6A and HHV-6B on a Rotor-Gene™ 6000 (Qiagen, Hilden, Germany). The fidelity of the PCR enzyme and purity of the DNA-extraction was controlled through amplification of the house-keeping gene, β-Actin, from every 12th sample. Presence and quality of extracted DNA from clinical specimens was quantified (ng/μL) using a Nanodrop (Thermo Fisher Scientific, Waltham, MA). We used a cut off of 200 copies/mL to be indicative of an active infection. Study participants were also tested for HIV and malaria according to standard hospital procedure.
| Statistical analysis
Data analysis was undertaken using SPSS version 21 (IBM, Armonk, NY). For study descriptives ( and controls except for mean temperature which was slightly higher 0.28°C in controls than cases P = 0.003 (Table 3) . No specimens were positive for HHV-6A.
| Comparison of FS and FSE
We then analyzed the data by looking at whether amongst our cases patients with FSE were more likely to test positive for HHV-6B infection.
We found that among children with FS, being classified as having FSE was (Table 4 ).
| DISCUSSION
In our study, HHV-6B was not associated with FS. These results are similar to four previous case-control studies, in which no association was found between HHV-6B infection and FS [23] [24] [25] [26] (Table 1) , although these studies were small and had various methodological weaknesses, such as only screening by PCR in cerebral spinal fluid (CSF) or blood. 24, 26 This stands in contrast to the Hall study in which HHV-6 infection was associated with a threefold increase in the prevalence of FS 6 and the panel of eight cross-sectional studies where HHV-6 infection is readily detected in children with FS with a median HHV-6 prevalence of 17.4% (range 6-26.2%) ( Table 1) . 29 The most important inconsistency between the different studies, is the range of diagnostic tools used, and these distinctions are important, as different PCR assay sensitivities and targets, and different serology methodologies and reagents will give different results. Importantly, HHV-6 species are latent in monocytes or macrophages, 37 or CD34 +ve progenitor cells 38, 39 and periodically reactivate subclinically, as evidenced by the ready detection of this virus in healthy children. 18 The Hall study, and all but one of the cross-sectional studies, included serological analysis to define HHV-6 primary infection. In our study, we did not use serology but based on median age ranges and previous studies it is possible that a significant percentage of the HHV-6 infections in this study are reactivations, as primary infection in Zambia peaks at around 9 months of age. 35 In the FEBSTAT study (US) median age was 14.8 months, and of the 58 HHV-6 and HHV-7 infections, 14 (31%) were reactivations. In our study, the median age was considerably higher (29. In poor communities in sub-Saharan Africa young infants are exposed to a high burden of infectious diseases, including neurological infections. A baseline study of MRI data from healthy Malawian teenagers found brain abnormalities in 18% (16/96) of children.
42
The observed incidental atrophy and white matter abnormalities are not seen in healthy US children, suggesting that the higher disease burden during early childhood may be responsible for these abnormalities. 42 Identifying the causal pathogens in this population group may inform on targets for vaccine development, that could prevent or reduce the incidence of CNS infections during infancy, impacting on acute disease burden and later developmental sequelae. poorly defined. 44 Ganciclovir is used at some centers in South Africa to treat CMV pneumonia in HIV-infected/exposed children. [45] [46] [47] HHV-6 has been shown to be sensitive to Artesunate and was used for the first time in a recent case study to treat a child with HHV-6 associated myocarditis. 48, 49 Artesunate is a drug already approved for the treatment of malaria and is widely available in Africa and could present a good drug candidate for future pilot trials looking at treating HHV-6 positive FSE in this population.
None of the samples tested positive for HHV-6A, similar to results from the FEBSTAT study in 2012 and mirroring results obtained in the earlier cross-sectional study of infants admitted to the hospital. 27, 35 However, this contrasts with an earlier study of healthy Zambian children that found HHV-6A to be more common.
18
A possible explanation for these inconsistencies could be the existence of novel recombinant HHV-6 viruses with components of both HHV-6A and HHV-6B, as evidence in a recent whole genome sequencing study in the US. 50 There are currently no full genome sequences for HHV-6A or HHV-6B from sub-Saharan Africa other than the two reference strains Z29 and U1102. 2 As more whole genomes become available it might help us better understand the molecular epidemiology of these viruses.
Limitations: Our study was not longitudinal and so we could not compare the clinical/virological course of patients or outcomes of HHV-6B infection in cases and controls. Lacking serial specimens and serological analysis we could not differentiate primary infections from reactivations/reinfections. We did not include CSF analysis as this is unreliable for detecting active HHV-6 infection and lumbar puncture is difficult to undertake in the research setting in Zambia due to low cultural acceptance. 51 Whilst rare, detection of HHV-6B in CSF makes a stronger case for direct pathology affecting the CNS, although 11/13 previous studies analyzed blood, including the influential Hall and
Epstein studies, and so our results are comparable. 6, 27 The low number of FSE cases on our study demands that the resulting odds ratio be viewed with caution and due respect for the wide confidence intervals.
We did not have access to maternal HIV status.
We conclude that this is the first case-control study to suggest an association between HHV-6B and FSE, which has been associated with increased risk of developing epilepsy in children with FS.
Epilepsy is highly prevalent in the Africa region and further studies should look at the virological course of HHV-6B and other candidate viral causes, in FSE patients, and correlate with long-term outcomes.
Artesunate is a possible affordable and accessible treatment option to be piloted for HHV-6 and other betaherpesvirus infections in the African setting.
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